© 2026 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY
WEDW-FM · WNPR · WPKT · WRLI-FM
Public Files Contact · ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Cancer Answers is hosted by Dr. Anees Chagpar, Associate Professor of Surgical Oncology and Director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven Hospital, and Dr. Francine Foss, Professor of Medical Oncology. The show features a guest cancer specialist who will share the most recent advances in cancer therapy and respond to listeners questions. Myths, facts and advances in cancer diagnosis and treatment are discussed, with a different focus eachweek. Nationally acclaimed specialists in various types of cancer research, diagnosis, and treatment discuss common misconceptions about the disease and respond to questions from the community.Listeners can submit questions to be answered on the program at canceranswers@yale.edu or by leaving a message at (888) 234-4YCC. As a resource, archived programs from 2006 through the present are available in both audio and written versions on the Yale Cancer Center website.

Doctors Are Slow To Adopt Changes In Breast Cancer Treatment

New evidence on the effectiveness of medical treatments can take a long time to influence medical practice.
Damian Dovarganes
/
AP
New evidence on the effectiveness of medical treatments can take a long time to influence medical practice.

Cancer doctors want the best, most effective treatment for their patients. But it turns out many aren't paying attention to evidence that older women with early stage breast cancer may be enduring the pain, fatigue and cost of radiation treatment although it doesn't increase life expectancy.

Researchers from Duke University Medical Center analyzed the impact of a large randomized trial published in 2004 that compared treatment options for women over the age of 70 with early-stage breast cancer. That study compared cancer recurrence and survival rates among women who had surgery, chemotherapy and radiation to that of women who had surgery and chemotherapy only.

While there was a slight decrease in recurrence of cancer in the group who had radiation, there was no difference in survival, thus raising the question of whether radiation treatment for this group of patients is worthwhile.

According to Dr. Rachel Blitzblau, a radiation oncologist at Duke University Medical Center and lead author of the study, which was published Monday in the journal Cancer, "we should consider omitting radiation for these women, because the small observed benefits might not be worth the side effects and costs."

Short-term side effects of radiation include skin blistering and fatigue. Long-term effects can include nerve damage and lymphedema, or swelling of the hand and arm.

Blitzblau and colleagues looked at practice patterns among cancer doctors, comparing the number of women who received radiation therapy prior to the 2004 findings and after. There was little difference, just a 7 percent drop in the number of women receiving radiation.

About 69 percent of patients treated between 2000 and 2004 got some form of radiation, compared with 62 percent 2005 and 2009.

"The publication of the trial had only a very small impact on practice patterns," she says, "our findings demonstrate the potential difficulty of incorporating clinical trial data that involves omitting a treatment that has been considered the standard of care." The study was published Monday in the journal Cancer,

It may be that doctors are simply uncomfortable suggesting that patients forego treatment even when high quality studies show little advantage, Blitzblau says, adding that it's important to improve "evidence-based medical practice in all medical specialties."

Copyright 2021 NPR. To see more, visit https://www.npr.org.

Award-winning journalist Patti Neighmond is NPR's health policy correspondent. Her reports air regularly on NPR newsmagazines All Things Considered, Morning Edition, and Weekend Edition.

Federal funding is gone.

Congress has eliminated all funding for public media.

That means $2.1 million per year that Connecticut Public relied on to deliver you news, information, and entertainment programs you enjoyed is gone.

The future of public media is in your hands.

All donations are appreciated, but we ask in this moment you consider starting a monthly gift as a Sustainer to help replace what’s been lost.

SOMOS CONNECTICUT is an initiative from Connecticut Public, the state’s local NPR and PBS station, to elevate Latino stories and expand programming that uplifts and informs our Latino communities. Visit CTPublic.org/latino for more stories and resources. For updates, sign up for the SOMOS CONNECTICUT newsletter at ctpublic.org/newsletters.

SOMOS CONNECTICUT es una iniciativa de Connecticut Public, la emisora local de NPR y PBS del estado, que busca elevar nuestras historias latinas y expandir programación que alza y informa nuestras comunidades latinas locales. Visita CTPublic.org/latino para más reportajes y recursos. Para noticias, suscríbase a nuestro boletín informativo en ctpublic.org/newsletters.

Federal funding is gone.

Congress has eliminated all funding for public media.

That means $2.1 million per year that Connecticut Public relied on to deliver you news, information, and entertainment programs you enjoyed is gone.

The future of public media is in your hands.

All donations are appreciated, but we ask in this moment you consider starting a monthly gift as a Sustainer to help replace what’s been lost.

Related Content